Evaulating Gene Therapy Assets in Preclinical Ocular Models

Time: 9:45 am
day: Day One

Details:

  • Species considerations for drug development of ocular gene therapy assets
  • Ocular routes of delivery for gene therapy in preclinical model
  • Efficacy and safety assessment of gene therapy assets in preclinical ocular models

Speakers: